Liver X factor
How Rgenix’s liver X agonist could help overcome checkpoint resistance in cancer
Rgenix Inc. is preparing to test its RGX-104 in combination with checkpoint inhibitors after Phase I data confirmed the company’s belief that the liver X receptor agonist depletes suppressive immune cells and increases T cell activating dendritic cells in humans.
In a poster presented on Oct. 29 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Rgenix reported results from an ongoing Phase Ia/Ib study of the small molecule agonist of liver X receptor beta (NR1H2; LXR-b) in treatment-experienced patients with solid tumors or lymphomas. At the time of analysis, four of 12 evaluable patients had stable disease at eight weeks. The maximum tolerated dose (MTD) had not been reached in the dose escalation phase.
The company also reported mechanistic data from the trial showing RGX-104 activates the immune system via multiple mechanisms that include